Acrux developed Dapsone 5%, Gel which was approved by the FDA in 2023 as an AB rated generic. The product is licensed to TruPharma. It was launched in the United States in 2024.
Dapsone Gel, 5% is indicated for the topical treatment of acne vulgaris. Refer to the Prescribing Information for further information on the product.
Refer to the Prescribing Information for further information on the product.